Skip to content
Company Analysis

Spero Therapeutics, Inc. SPRO

A comprehensive view of key metrics, scores, and financial health for Spero Therapeutics, Inc.

Overview of Spero Therapeutics, Inc.

SPRO NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Spero Therapeutics, Inc. (SPRO), is a Micro Cap company, in the Biotechnology industry, last closed at $1.19, about 81.5% undervalued vs fair value, -37.4% 1Y return, ranked 396/1145 in sector.
Metrics P/E 16.0× Rev Growth 117.6% ROE 16.3%
USD 1.19
-1.65%
(Delayed)
• Vol 90d: 84.9%
52-Week Range
Market Cap
$122.75M
Enterprise Value
$74.02M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Good
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Good
Completeness: 94%
Confidence: 60%
Updated: Sep 12
Top Beats
No strong beats yet

Quick Facts

Website https://sperotherapeutics.com
HQ Cambridge, MA
Employees 32
Fiscal year Dec 31

Next Events

Earnings Nov 12

Fair Value Snapshot

Bear Base Bull
$2
$2
$2
Current: $1.19 +82% vs base

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$40.3M
-23.9%%
Total Revenue
$59.6M
117.6%%
Net Income
$8.6M
112.5%%
Operating Expense
$52.5M
-47.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
38.3 months
Excellent

Strong cash position with 2+ years of runway

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Spero Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
67
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • ROIC Sustainably Above Peers ROIC at 86.3th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Cost Leadership Position Operating margin at 89.9th percentile with strong OpEx control demonstrates cost leadership.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 9.6th percentile with high volatility suggests weak pricing power or commoditized products.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.17), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
49
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger

Where management spends the performance budget

Insufficient Data for Analysis

SPRO - Spero Therapeutics, Inc.

We have limited financial data for SPRO. The Growth and Profitability axes don't have enough metrics for reliable analysis.

Data Coverage by Axis

Growth
0% coverage Below threshold
Profitability
0% coverage N/A
Overall Coverage: 33.3% (Minimum 40% required)

What This Means

  • Currently at 33.3% data coverage (minimum 40% required)
  • Limited peer data available for industry benchmarking
  • Check back after quarterly or annual filings
  • Some metrics may not be applicable to this company's business model

What can you do?

  • View available sections like Moat Map or Engine Room for partial insights
  • Set up a watchlist alert to be notified when new data becomes available
  • Compare with peers in the same industry that have complete data

Two Futures

Scenario-based fair value ranges for Spero Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$2.16
- - -
+81.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000